Clinical Pearls about the Referral Process of Bispecifics and CAR-T in RRMM

The discussion shares key takeaways and practical insights for optimizing the referral and treatment process for CAR T-cell and bispecific therapies.

EP: 1.Importance of Collaboration between Academic and Community Centers

EP: 2.Referral Process: Streamlining and Challenges Seen

EP: 3.Referral Process: Bispecifics

EP: 4.Similarities and Differences among Bispecifics: BCMA vs non-BCMA

EP: 5.Types of Referrals and Impact of Social Factors on the Referral Process

EP: 6.Managing AEs Seen with Bispecifics

EP: 7.Referral Process: CAR T-Cell Therapy

EP: 8.CAR T: Impact of Recent Approvals on the Referral Process

EP: 9.Long-Term Monitoring of AEs and Reintegrating Patients back into Community Care

Now Viewing

EP: 10.Clinical Pearls about the Referral Process of Bispecifics and CAR-T in RRMM

Video content above is prompted by the following:

Please share some key takeaways/pearls.

Recent Videos